VRCI vs. AGL, ABDX, YGEN, GDR, GENI, PRM, LLAI, IDHC, DMTR, and LLA
Should you be buying Verici Dx stock or one of its competitors? The main competitors of Verici Dx include ANGLE (AGL), Abingdon Health (ABDX), Yourgene Health (YGEN), genedrive (GDR), GENinCode (GENI), Proteome Sciences (PRM), LungLife AI (LLAI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.
ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
Verici Dx has higher revenue and earnings than ANGLE. Verici Dx is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
ANGLE currently has a consensus target price of GBX 70, suggesting a potential upside of 775.00%. Given ANGLE's higher probable upside, equities analysts clearly believe ANGLE is more favorable than Verici Dx.
ANGLE has a net margin of 0.00% compared to Verici Dx's net margin of -110.99%. Verici Dx's return on equity of -58.12% beat ANGLE's return on equity.
In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that ANGLE is being referred to more favorably in the media.
ANGLE received 182 more outperform votes than Verici Dx when rated by MarketBeat users.
18.8% of ANGLE shares are owned by institutional investors. Comparatively, 51.9% of Verici Dx shares are owned by institutional investors. 16.2% of ANGLE shares are owned by company insiders. Comparatively, 17.1% of Verici Dx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Verici Dx has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Summary
Verici Dx beats ANGLE on 8 of the 15 factors compared between the two stocks.
Get Verici Dx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verici Dx Competitors List
Related Companies and Tools
This page (LON:VRCI) was last updated on 10/9/2024 by MarketBeat.com Staff
Free VRCI Stock Alerts